View Financial HealthSyntara 配当と自社株買い配当金 基準チェック /06Syntara配当金を支払った記録がありません。主要情報n/a配当利回り-5.4%バイバック利回り総株主利回り-5.4%将来の配当利回り0%配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesBoard Change • May 20High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 2 experienced directors. 2 highly experienced directors. CEO, MD & Director Gary Phillips is the most experienced director on the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Apr 29+ 1 more updateSyntara Limited has filed a Follow-on Equity Offering in the amount of AUD 8 million.Syntara Limited has filed a Follow-on Equity Offering in the amount of AUD 8 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 242,605,411 Price\Range: AUD 0.027 Discount Per Security: AUD 0.00162 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 53,690,885 Price\Range: AUD 0.027 Discount Per Security: AUD 0.00162 Transaction Features: Subsequent Direct Listingお知らせ • Jan 08Syntara Limited Announces Company Secretary Changes, Effective January 8, 2026Syntara Limited announced that existing Chief Financial Officer, Mr. Tim Luscombe, has been appointed as Company Secretary of the company, effective January 8, 2026. For the purposes of ASX Listing Rule 12.6, Mr. Tim Luscombe will be the person responsible for communications with ASX in relation to Listing Rule matters. Mr. Cameron Billingsley has notified the Board of his resignation as Company Secretary, effective January 8, 2026. Mr. Billingsley will continue to provide external general counsel services to Syntara.お知らせ • Oct 01Syntara Limited, Annual General Meeting, Nov 20, 2025Syntara Limited, Annual General Meeting, Nov 20, 2025.お知らせ • Apr 30Syntara Limited to Report Q3, 2025 Results on May 01, 2025Syntara Limited announced that they will report Q3, 2025 results on May 01, 2025お知らせ • Feb 06Syntara Limited Announces Board ChangesSyntara Limited announced that Cameron Billingsley has been appointed as Company Secretary, effective February 6, 2025. Mr. David McGarvey has notified the Board of his resignation as Company Secretary, effective today. Syntara thanks Mr. McGarvey for his significant contribution to the Company for more than 20 years.お知らせ • Dec 12Syntara Limited has completed a Follow-on Equity Offering in the amount of AUD 15 million.Syntara Limited has completed a Follow-on Equity Offering in the amount of AUD 15 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 205,971,256 Price\Range: AUD 0.06 Discount Per Security: AUD 0.0036 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 34,275,302 Price\Range: AUD 0.06 Discount Per Security: AUD 0.0036 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 9,753,442 Price\Range: AUD 0.06 Discount Per Security: AUD 0.0036 Transaction Features: Subsequent Direct Listingお知らせ • Dec 10Syntara Limited Announces Positive Interim Data in Phase 2 Study of SNT-5505 in MyelofibrosisSyntara Limited announced positive interim data from its ongoing Phase 2 clinical trial evaluating SNT-5505 (200 mg BID) in combination with ruxolitinib (RUX) for the treatment of myelofibrosis (MF)1. The interim results suggest that SNT-5505 has potential as a breakthrough therapy for MF and are being presented at the 66thAmerican Society of Hematology annual meeting (ASH). Highlights: At 12 weeks of treatment, 46% of evaluable patients3 achieved a 50% improvement in Total Symptom Score (TSS50) which improved to 80% at 38 weeks of treatment. TSS50 is a standard efficacy endpoint used as the primary endpoint in MF clinical trials. 30% of evaluable patients4 achieved a spleen volume reduction (SVR) of 25% and 20% achieved an SVR of 35%. Both levels are considered clinically meaningful, with SVR35 a typical endpoint used in MF clinical trials. Patient symptoms and spleen volume continued to improve over the duration of the interim data which is a novel finding that differentiates SNT-5505 from MF drugs on market and in later stages of development. SNT-5505 is safe & well tolerated with no treatment related serious adverse events noted at this interim stage - viewed together with the excellent safety profile seen in the earlier monotherapy study5 this is emerging as another key differentiator to MF drugs on the market and in development. After receiving data from a subset of patients reaching 52 weeks of treatment by March 2025, the company intends to discuss with the FDA the trial design for a pivotal Phase 2c/3 study. Concurrently, the company will also engage with potential global and regional partners. There were no treatment related serious adverse events (SAEs) attributed to SNT-5505. Substantial symptom relief observed over time: At Week 12 - 46% (6/13) of evaluable patients achieved a 50% reduction in Myelofibrosis Symptom Assessment Form Total Symptom score (TSS50), a benchmark for clinical response recognised by regulatory authorities such as the FDA. At Week 38 - 80% (4/5) of evaluable patients achieved an TSS50. Of the 16 enrolled patients, 12 patients were continuing to receive treatment as of the ASH data cut off. No discontinuations for adverse events were considered related to SNT-5505 treatment. This level of discontinuations in clinical trials is consistent with a patient group with a high disease burden. The Phase 2 trial has been designed to evaluate SNT-5505 in combination with RUX in patients with intermediate-2 or high-risk MF.お知らせ • Oct 29Syntara Limited to Report Q1, 2025 Results on Oct 30, 2024Syntara Limited announced that they will report Q1, 2025 results Pre-Market on Oct 30, 2024お知らせ • Sep 30Syntara Limited, Annual General Meeting, Nov 28, 2024Syntara Limited, Annual General Meeting, Nov 28, 2024.New Risk • Sep 01New minor risk - Revenue sizeThe company makes less than US$5m in revenue. Total revenue: AU$5.9m (US$4.0m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Shareholders have been substantially diluted in the past year (79% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (AU$4.5m net loss in 2 years). Revenue is less than US$5m (AU$5.9m revenue, or US$4.0m). Market cap is less than US$100m (€26.9m market cap, or US$29.7m).お知らせ • Aug 16Syntara Limited Announces CFO ChangesSyntara Limited announced the appointment of Tim Luscombe as Chief Financial Officer (CFO) for Syntara, effective 31 August 2024. Tim replaces Mr. David McGarvey, who is retiring after more than 20 years as the CFO of Syntara, and before that Pharmaxis. David will continue in his role as Company Secretary to the Board. Tim is a Director at Bio101 Financial Advisory (Bio101), a financial services firm providing outsourced CFO, taxation and company secretarial solutions to the biotechnology and healthcare sector. Tim has more than 10 years of finance and commercial experience working with public and private companies in Australia and abroad. He currently serves as a CFO and Company Secretary for several ASX-listed, public unlisted and private companies. Tim holds a Bachelor of Commerce from the University of Melbourne, a Certificate in Governance Practice from the Governance Institute of Australia and is a qualified Chartered Accountant. In addition to his role as Company Secretary Mr. McGarvey will give special attention to concluding financial and legal arrangements associated with the sale of the mannitol business unit.New Risk • Jul 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$15m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$15m free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Shareholders have been substantially diluted in the past year (66% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (AU$6.7m net loss in 2 years). Market cap is less than US$100m (€17.8m market cap, or US$19.1m).New Risk • Jun 16New minor risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow. Free cash flow: -AU$15m This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). Shareholders have been substantially diluted in the past year (66% increase in shares outstanding). Minor Risks Less than 1 year of cash runway based on current free cash flow (-AU$15m). Currently unprofitable and not forecast to become profitable over next 2 years (AU$6.7m net loss in 2 years). Market cap is less than US$100m (€21.4m market cap, or US$22.9m).New Risk • May 29New minor risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow. Free cash flow: -AU$11m This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Shareholders have been substantially diluted in the past year (66% increase in shares outstanding). Minor Risks Less than 1 year of cash runway based on current free cash flow (-AU$11m). Currently unprofitable and not forecast to become profitable over next 2 years (AU$6.7m net loss in 2 years). Market cap is less than US$100m (€15.3m market cap, or US$16.6m).お知らせ • Apr 24Syntara Limited to Report Q3, 2024 Results on Apr 30, 2024Syntara Limited announced that they will report Q3, 2024 results on Apr 30, 2024Breakeven Date Change • Mar 05No longer forecast to breakevenThe analyst covering Syntara no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of AU$14.7m in 2026. New forecast suggests the company will make a loss of AU$4.50m in 2026.New Risk • Feb 07New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 64% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (28% average weekly change). Shareholders have been substantially diluted in the past year (64% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable next year (AU$12m net loss next year). Market cap is less than US$100m (€15.0m market cap, or US$16.1m).お知らせ • Feb 06Syntara Limited has completed a Follow-on Equity Offering in the amount of AUD 10 million.Syntara Limited has completed a Follow-on Equity Offering in the amount of AUD 10 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 108,392,130 Price\Range: AUD 0.022 Discount Per Security: AUD 0.00022 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 346,153,325 Price\Range: AUD 0.022 Discount Per Security: AUD 0.00022 Transaction Features: Subsequent Direct Listingお知らせ • Dec 20Syntara Limited has filed a Follow-on Equity Offering in the amount of AUD 10.0012 million.Syntara Limited has filed a Follow-on Equity Offering in the amount of AUD 10.0012 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 108,400,000 Price\Range: AUD 0.022 Discount Per Security: AUD 0.00022 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 346,200,000 Price\Range: AUD 0.022 Discount Per Security: AUD 0.00022 Transaction Features: Subsequent Direct ListingNew Risk • Dec 02New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$16m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$16m free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (AU$3.5m net loss in 2 years). Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (€13.3m market cap, or US$14.5m).お知らせ • Oct 20Arna Pharma Pty Ltd completed the acquisition of Mannitol respiratory business of Pharmaxis.Arna Pharma Pty Ltd entered into definitive agreement to acquire Mannitol respiratory business of Pharmaxis on October 3, 2023. the sale is scheduled to complete before the end of October 2023. Arna Pharma Pty Ltd completed the acquisition of Mannitol respiratory business of Pharmaxis on October 19, 2023.Board Change • Oct 18Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non-Executive Director Simon Green was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Oct 05Arna Pharma Pty Ltd entered into definitive agreement to acquire Mannitol respiratory business of Pharmaxis.Arna Pharma Pty Ltd entered into definitive agreement to acquire Mannitol respiratory business of Pharmaxis on October 3, 2023. the sale is scheduled to complete before the end of October 2023.お知らせ • Sep 13Pharmaxis Ltd, Annual General Meeting, Nov 28, 2023Pharmaxis Ltd, Annual General Meeting, Nov 28, 2023, at 11:01 AUS Eastern Standard Time.Reported Earnings • Aug 28Full year 2023 earnings released: EPS: AU$0 (vs AU$0.003 loss in FY 2022)Full year 2023 results: EPS: AU$0. Revenue: AU$19.3m (up 23% from FY 2022). Net loss: AU$11.4m (loss widened 487% from FY 2022). Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Pharmaceuticals industry in Germany.Breakeven Date Change • Aug 28Forecast to breakeven in 2026The 2 analysts covering Pharmaxis expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of AU$14.7m in 2026. Average annual earnings growth of 44% is required to achieve expected profit on schedule.New Risk • Aug 13New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings are forecast to decline by an average of 42% per year for the foreseeable future. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (31% increase in shares outstanding). Market cap is less than US$100m (€21.4m market cap, or US$23.4m).Reported Earnings • Feb 12Second quarter 2023 earnings released: AU$0.008 loss per share (vs AU$0.01 loss in 2Q 2022)Second quarter 2023 results: AU$0.008 loss per share. Revenue: AU$1.05m (down 62% from 2Q 2022). Net loss: AU$5.82m (loss widened 3.1% from 2Q 2022). Revenue is forecast to grow 2.8% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Pharmaceuticals industry in Germany.お知らせ • Jan 17Pharmaxis Ltd Appoints Hashan De Silva to the Board as Nonexecutive DirectorPharmaxis Ltd. announced the appointment of healthcare investment professional Hashan De Silva to the Board as a nonexecutive director. Mr. De Silva is an experienced life sciences investment professional. He worked as associate healthcare analyst at Macquarie Group and lead healthcare analyst at CLSA Australia before joining Karst Peak Capital in February 2021 as head of healthcare research. Prior to moving into life science investment Mr. De Silva worked at Eli Lilly in various roles focused on the commercialisation of new and existing pharmaceuticals. Mr. De Silva was educated at the University of New South Wales (Bachelor's Degree in Medicine and Master's Degree in Finance) and is a Chartered Financial Analyst. Until December 2022 Mr. De Silva was Head of Healthcare Research at Karst Peak Capital Limited, a Hong Kong and Australian based specialist healthcare fund and is a nonexecutive director of Melbourne and Philadelphia based CurveBeam AI. Mr. De Silva is based in Sydney Australia and commences his role as nonexecutive director on 16 January 2023.お知らせ • Nov 30+ 2 more updatesPharmaxis Ltd to Report Q3, 2023 Results on Apr 28, 2023Pharmaxis Ltd announced that they will report Q3, 2023 results on Apr 28, 2023Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Chairman of the Board Malcolm McComas was the last independent director to join the board, commencing their role in 2003. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 02First quarter 2023 earnings releasedFirst quarter 2023 results: EPS: AU$0.002. Revenue: AU$8.08m (up 41% from 1Q 2022). Net income: AU$943.0k (up AU$4.12m from 1Q 2022). Profit margin: 12% (up from net loss in 1Q 2022). The move to profitability was primarily driven by higher revenue. Revenue is expected to decline by 1.3% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Germany are expected to grow by 4.1%. Over the last 3 years on average, earnings per share has increased by 76% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings.Reported Earnings • Sep 01Full year 2022 earnings released: AU$0.003 loss per share (vs AU$0.007 loss in FY 2021)Full year 2022 results: AU$0.003 loss per share (up from AU$0.007 loss in FY 2021). Revenue: AU$15.8m (down 33% from FY 2021). Net loss: AU$1.94m (loss narrowed 35% from FY 2021). Over the next year, revenue is expected to shrink by 4.8% compared to a 6.8% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 01Full year 2022 earnings releasedFull year 2022 results: Revenue: AU$15.9m (down 33% from FY 2021). Net loss: AU$1.93m (loss narrowed 35% from FY 2021). Over the next year, revenue is expected to shrink by 18% compared to a 8.0% growth forecast for the pharmaceuticals industry in Germany.Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Chairman of the Board Malcolm McComas was the last independent director to join the board, commencing their role in 2003. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Feb 11Second quarter 2022 earnings: Revenues exceed analyst expectationsSecond quarter 2022 results: Revenue: AU$2.78m (down 78% from 2Q 2021). Net loss: AU$5.65m (down 212% from profit in 2Q 2021). Revenue exceeded analyst estimates by 2.5%. Over the last 3 years on average, earnings per share has increased by 72% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.Recent Insider Transactions • Dec 28Independent Chairman of the Board recently bought €71k worth of stockOn the 21st of December, Malcolm McComas bought around 1m shares on-market at roughly €0.07 per share. This was the largest purchase by an insider in the last 3 months. Malcolm has been a buyer over the last 12 months, purchasing a net total of €99k worth in shares.Reported Earnings • Oct 29First quarter 2022 earnings released: AU$0.007 loss per shareThe company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2022 results: Revenue: AU$5.74m (up 457% from 1Q 2021). Net loss: AU$3.18m (loss narrowed 36% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.Reported Earnings • Jan 30Second quarter 2021 earnings releasedThe company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: AU$12.6m (up AU$11.0m from 2Q 2020). Net income: AU$5.03m (up AU$9.60m from 2Q 2020). Profit margin: 40% (up from net loss in 2Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has only fallen by 26% per year, which means it has not declined as severely as earnings.Analyst Estimate Surprise Post Earnings • Jan 30Revenue misses expectationsRevenue missed analyst estimates by 1.5%. Over the next year, revenue is expected to shrink by 5.5% compared to a 2.4% growth forecast for the Pharmaceuticals industry in Germany.Reported Earnings • Oct 30First quarter earnings releasedOver the last 12 months the company has reported total losses of AU$13.2m, with losses narrowing by 28% from the prior year. Total revenue was AU$11.4m over the last 12 months, down 14% from the prior year.決済の安定と成長配当データの取得安定した配当: UUDAの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: UUDAの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Syntara 配当利回り対市場UUDA 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (UUDA)n/a市場下位25% (DE)1.5%市場トップ25% (DE)4.5%業界平均 (Pharmaceuticals)2.7%アナリスト予想 (UUDA) (最長3年)0%注目すべき配当: UUDAは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: UUDAは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: UUDAの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: UUDAが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YDE 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/23 03:27終値2026/05/20 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Syntara Limited 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。9 アナリスト機関Anubhav SaxenaBell PotterThomas WakimBell PotterMadeleine WilliamsCanaccord Genuity6 その他のアナリストを表示
Board Change • May 20High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 2 experienced directors. 2 highly experienced directors. CEO, MD & Director Gary Phillips is the most experienced director on the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Apr 29+ 1 more updateSyntara Limited has filed a Follow-on Equity Offering in the amount of AUD 8 million.Syntara Limited has filed a Follow-on Equity Offering in the amount of AUD 8 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 242,605,411 Price\Range: AUD 0.027 Discount Per Security: AUD 0.00162 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 53,690,885 Price\Range: AUD 0.027 Discount Per Security: AUD 0.00162 Transaction Features: Subsequent Direct Listing
お知らせ • Jan 08Syntara Limited Announces Company Secretary Changes, Effective January 8, 2026Syntara Limited announced that existing Chief Financial Officer, Mr. Tim Luscombe, has been appointed as Company Secretary of the company, effective January 8, 2026. For the purposes of ASX Listing Rule 12.6, Mr. Tim Luscombe will be the person responsible for communications with ASX in relation to Listing Rule matters. Mr. Cameron Billingsley has notified the Board of his resignation as Company Secretary, effective January 8, 2026. Mr. Billingsley will continue to provide external general counsel services to Syntara.
お知らせ • Oct 01Syntara Limited, Annual General Meeting, Nov 20, 2025Syntara Limited, Annual General Meeting, Nov 20, 2025.
お知らせ • Apr 30Syntara Limited to Report Q3, 2025 Results on May 01, 2025Syntara Limited announced that they will report Q3, 2025 results on May 01, 2025
お知らせ • Feb 06Syntara Limited Announces Board ChangesSyntara Limited announced that Cameron Billingsley has been appointed as Company Secretary, effective February 6, 2025. Mr. David McGarvey has notified the Board of his resignation as Company Secretary, effective today. Syntara thanks Mr. McGarvey for his significant contribution to the Company for more than 20 years.
お知らせ • Dec 12Syntara Limited has completed a Follow-on Equity Offering in the amount of AUD 15 million.Syntara Limited has completed a Follow-on Equity Offering in the amount of AUD 15 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 205,971,256 Price\Range: AUD 0.06 Discount Per Security: AUD 0.0036 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 34,275,302 Price\Range: AUD 0.06 Discount Per Security: AUD 0.0036 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 9,753,442 Price\Range: AUD 0.06 Discount Per Security: AUD 0.0036 Transaction Features: Subsequent Direct Listing
お知らせ • Dec 10Syntara Limited Announces Positive Interim Data in Phase 2 Study of SNT-5505 in MyelofibrosisSyntara Limited announced positive interim data from its ongoing Phase 2 clinical trial evaluating SNT-5505 (200 mg BID) in combination with ruxolitinib (RUX) for the treatment of myelofibrosis (MF)1. The interim results suggest that SNT-5505 has potential as a breakthrough therapy for MF and are being presented at the 66thAmerican Society of Hematology annual meeting (ASH). Highlights: At 12 weeks of treatment, 46% of evaluable patients3 achieved a 50% improvement in Total Symptom Score (TSS50) which improved to 80% at 38 weeks of treatment. TSS50 is a standard efficacy endpoint used as the primary endpoint in MF clinical trials. 30% of evaluable patients4 achieved a spleen volume reduction (SVR) of 25% and 20% achieved an SVR of 35%. Both levels are considered clinically meaningful, with SVR35 a typical endpoint used in MF clinical trials. Patient symptoms and spleen volume continued to improve over the duration of the interim data which is a novel finding that differentiates SNT-5505 from MF drugs on market and in later stages of development. SNT-5505 is safe & well tolerated with no treatment related serious adverse events noted at this interim stage - viewed together with the excellent safety profile seen in the earlier monotherapy study5 this is emerging as another key differentiator to MF drugs on the market and in development. After receiving data from a subset of patients reaching 52 weeks of treatment by March 2025, the company intends to discuss with the FDA the trial design for a pivotal Phase 2c/3 study. Concurrently, the company will also engage with potential global and regional partners. There were no treatment related serious adverse events (SAEs) attributed to SNT-5505. Substantial symptom relief observed over time: At Week 12 - 46% (6/13) of evaluable patients achieved a 50% reduction in Myelofibrosis Symptom Assessment Form Total Symptom score (TSS50), a benchmark for clinical response recognised by regulatory authorities such as the FDA. At Week 38 - 80% (4/5) of evaluable patients achieved an TSS50. Of the 16 enrolled patients, 12 patients were continuing to receive treatment as of the ASH data cut off. No discontinuations for adverse events were considered related to SNT-5505 treatment. This level of discontinuations in clinical trials is consistent with a patient group with a high disease burden. The Phase 2 trial has been designed to evaluate SNT-5505 in combination with RUX in patients with intermediate-2 or high-risk MF.
お知らせ • Oct 29Syntara Limited to Report Q1, 2025 Results on Oct 30, 2024Syntara Limited announced that they will report Q1, 2025 results Pre-Market on Oct 30, 2024
お知らせ • Sep 30Syntara Limited, Annual General Meeting, Nov 28, 2024Syntara Limited, Annual General Meeting, Nov 28, 2024.
New Risk • Sep 01New minor risk - Revenue sizeThe company makes less than US$5m in revenue. Total revenue: AU$5.9m (US$4.0m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Shareholders have been substantially diluted in the past year (79% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (AU$4.5m net loss in 2 years). Revenue is less than US$5m (AU$5.9m revenue, or US$4.0m). Market cap is less than US$100m (€26.9m market cap, or US$29.7m).
お知らせ • Aug 16Syntara Limited Announces CFO ChangesSyntara Limited announced the appointment of Tim Luscombe as Chief Financial Officer (CFO) for Syntara, effective 31 August 2024. Tim replaces Mr. David McGarvey, who is retiring after more than 20 years as the CFO of Syntara, and before that Pharmaxis. David will continue in his role as Company Secretary to the Board. Tim is a Director at Bio101 Financial Advisory (Bio101), a financial services firm providing outsourced CFO, taxation and company secretarial solutions to the biotechnology and healthcare sector. Tim has more than 10 years of finance and commercial experience working with public and private companies in Australia and abroad. He currently serves as a CFO and Company Secretary for several ASX-listed, public unlisted and private companies. Tim holds a Bachelor of Commerce from the University of Melbourne, a Certificate in Governance Practice from the Governance Institute of Australia and is a qualified Chartered Accountant. In addition to his role as Company Secretary Mr. McGarvey will give special attention to concluding financial and legal arrangements associated with the sale of the mannitol business unit.
New Risk • Jul 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$15m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$15m free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Shareholders have been substantially diluted in the past year (66% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (AU$6.7m net loss in 2 years). Market cap is less than US$100m (€17.8m market cap, or US$19.1m).
New Risk • Jun 16New minor risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow. Free cash flow: -AU$15m This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). Shareholders have been substantially diluted in the past year (66% increase in shares outstanding). Minor Risks Less than 1 year of cash runway based on current free cash flow (-AU$15m). Currently unprofitable and not forecast to become profitable over next 2 years (AU$6.7m net loss in 2 years). Market cap is less than US$100m (€21.4m market cap, or US$22.9m).
New Risk • May 29New minor risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow. Free cash flow: -AU$11m This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Shareholders have been substantially diluted in the past year (66% increase in shares outstanding). Minor Risks Less than 1 year of cash runway based on current free cash flow (-AU$11m). Currently unprofitable and not forecast to become profitable over next 2 years (AU$6.7m net loss in 2 years). Market cap is less than US$100m (€15.3m market cap, or US$16.6m).
お知らせ • Apr 24Syntara Limited to Report Q3, 2024 Results on Apr 30, 2024Syntara Limited announced that they will report Q3, 2024 results on Apr 30, 2024
Breakeven Date Change • Mar 05No longer forecast to breakevenThe analyst covering Syntara no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of AU$14.7m in 2026. New forecast suggests the company will make a loss of AU$4.50m in 2026.
New Risk • Feb 07New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 64% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (28% average weekly change). Shareholders have been substantially diluted in the past year (64% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable next year (AU$12m net loss next year). Market cap is less than US$100m (€15.0m market cap, or US$16.1m).
お知らせ • Feb 06Syntara Limited has completed a Follow-on Equity Offering in the amount of AUD 10 million.Syntara Limited has completed a Follow-on Equity Offering in the amount of AUD 10 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 108,392,130 Price\Range: AUD 0.022 Discount Per Security: AUD 0.00022 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 346,153,325 Price\Range: AUD 0.022 Discount Per Security: AUD 0.00022 Transaction Features: Subsequent Direct Listing
お知らせ • Dec 20Syntara Limited has filed a Follow-on Equity Offering in the amount of AUD 10.0012 million.Syntara Limited has filed a Follow-on Equity Offering in the amount of AUD 10.0012 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 108,400,000 Price\Range: AUD 0.022 Discount Per Security: AUD 0.00022 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 346,200,000 Price\Range: AUD 0.022 Discount Per Security: AUD 0.00022 Transaction Features: Subsequent Direct Listing
New Risk • Dec 02New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$16m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$16m free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (AU$3.5m net loss in 2 years). Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (€13.3m market cap, or US$14.5m).
お知らせ • Oct 20Arna Pharma Pty Ltd completed the acquisition of Mannitol respiratory business of Pharmaxis.Arna Pharma Pty Ltd entered into definitive agreement to acquire Mannitol respiratory business of Pharmaxis on October 3, 2023. the sale is scheduled to complete before the end of October 2023. Arna Pharma Pty Ltd completed the acquisition of Mannitol respiratory business of Pharmaxis on October 19, 2023.
Board Change • Oct 18Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non-Executive Director Simon Green was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Oct 05Arna Pharma Pty Ltd entered into definitive agreement to acquire Mannitol respiratory business of Pharmaxis.Arna Pharma Pty Ltd entered into definitive agreement to acquire Mannitol respiratory business of Pharmaxis on October 3, 2023. the sale is scheduled to complete before the end of October 2023.
お知らせ • Sep 13Pharmaxis Ltd, Annual General Meeting, Nov 28, 2023Pharmaxis Ltd, Annual General Meeting, Nov 28, 2023, at 11:01 AUS Eastern Standard Time.
Reported Earnings • Aug 28Full year 2023 earnings released: EPS: AU$0 (vs AU$0.003 loss in FY 2022)Full year 2023 results: EPS: AU$0. Revenue: AU$19.3m (up 23% from FY 2022). Net loss: AU$11.4m (loss widened 487% from FY 2022). Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Pharmaceuticals industry in Germany.
Breakeven Date Change • Aug 28Forecast to breakeven in 2026The 2 analysts covering Pharmaxis expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of AU$14.7m in 2026. Average annual earnings growth of 44% is required to achieve expected profit on schedule.
New Risk • Aug 13New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings are forecast to decline by an average of 42% per year for the foreseeable future. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (31% increase in shares outstanding). Market cap is less than US$100m (€21.4m market cap, or US$23.4m).
Reported Earnings • Feb 12Second quarter 2023 earnings released: AU$0.008 loss per share (vs AU$0.01 loss in 2Q 2022)Second quarter 2023 results: AU$0.008 loss per share. Revenue: AU$1.05m (down 62% from 2Q 2022). Net loss: AU$5.82m (loss widened 3.1% from 2Q 2022). Revenue is forecast to grow 2.8% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Pharmaceuticals industry in Germany.
お知らせ • Jan 17Pharmaxis Ltd Appoints Hashan De Silva to the Board as Nonexecutive DirectorPharmaxis Ltd. announced the appointment of healthcare investment professional Hashan De Silva to the Board as a nonexecutive director. Mr. De Silva is an experienced life sciences investment professional. He worked as associate healthcare analyst at Macquarie Group and lead healthcare analyst at CLSA Australia before joining Karst Peak Capital in February 2021 as head of healthcare research. Prior to moving into life science investment Mr. De Silva worked at Eli Lilly in various roles focused on the commercialisation of new and existing pharmaceuticals. Mr. De Silva was educated at the University of New South Wales (Bachelor's Degree in Medicine and Master's Degree in Finance) and is a Chartered Financial Analyst. Until December 2022 Mr. De Silva was Head of Healthcare Research at Karst Peak Capital Limited, a Hong Kong and Australian based specialist healthcare fund and is a nonexecutive director of Melbourne and Philadelphia based CurveBeam AI. Mr. De Silva is based in Sydney Australia and commences his role as nonexecutive director on 16 January 2023.
お知らせ • Nov 30+ 2 more updatesPharmaxis Ltd to Report Q3, 2023 Results on Apr 28, 2023Pharmaxis Ltd announced that they will report Q3, 2023 results on Apr 28, 2023
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Chairman of the Board Malcolm McComas was the last independent director to join the board, commencing their role in 2003. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 02First quarter 2023 earnings releasedFirst quarter 2023 results: EPS: AU$0.002. Revenue: AU$8.08m (up 41% from 1Q 2022). Net income: AU$943.0k (up AU$4.12m from 1Q 2022). Profit margin: 12% (up from net loss in 1Q 2022). The move to profitability was primarily driven by higher revenue. Revenue is expected to decline by 1.3% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Germany are expected to grow by 4.1%. Over the last 3 years on average, earnings per share has increased by 76% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings.
Reported Earnings • Sep 01Full year 2022 earnings released: AU$0.003 loss per share (vs AU$0.007 loss in FY 2021)Full year 2022 results: AU$0.003 loss per share (up from AU$0.007 loss in FY 2021). Revenue: AU$15.8m (down 33% from FY 2021). Net loss: AU$1.94m (loss narrowed 35% from FY 2021). Over the next year, revenue is expected to shrink by 4.8% compared to a 6.8% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 01Full year 2022 earnings releasedFull year 2022 results: Revenue: AU$15.9m (down 33% from FY 2021). Net loss: AU$1.93m (loss narrowed 35% from FY 2021). Over the next year, revenue is expected to shrink by 18% compared to a 8.0% growth forecast for the pharmaceuticals industry in Germany.
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Chairman of the Board Malcolm McComas was the last independent director to join the board, commencing their role in 2003. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Feb 11Second quarter 2022 earnings: Revenues exceed analyst expectationsSecond quarter 2022 results: Revenue: AU$2.78m (down 78% from 2Q 2021). Net loss: AU$5.65m (down 212% from profit in 2Q 2021). Revenue exceeded analyst estimates by 2.5%. Over the last 3 years on average, earnings per share has increased by 72% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.
Recent Insider Transactions • Dec 28Independent Chairman of the Board recently bought €71k worth of stockOn the 21st of December, Malcolm McComas bought around 1m shares on-market at roughly €0.07 per share. This was the largest purchase by an insider in the last 3 months. Malcolm has been a buyer over the last 12 months, purchasing a net total of €99k worth in shares.
Reported Earnings • Oct 29First quarter 2022 earnings released: AU$0.007 loss per shareThe company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2022 results: Revenue: AU$5.74m (up 457% from 1Q 2021). Net loss: AU$3.18m (loss narrowed 36% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.
Reported Earnings • Jan 30Second quarter 2021 earnings releasedThe company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: AU$12.6m (up AU$11.0m from 2Q 2020). Net income: AU$5.03m (up AU$9.60m from 2Q 2020). Profit margin: 40% (up from net loss in 2Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has only fallen by 26% per year, which means it has not declined as severely as earnings.
Analyst Estimate Surprise Post Earnings • Jan 30Revenue misses expectationsRevenue missed analyst estimates by 1.5%. Over the next year, revenue is expected to shrink by 5.5% compared to a 2.4% growth forecast for the Pharmaceuticals industry in Germany.
Reported Earnings • Oct 30First quarter earnings releasedOver the last 12 months the company has reported total losses of AU$13.2m, with losses narrowing by 28% from the prior year. Total revenue was AU$11.4m over the last 12 months, down 14% from the prior year.